Study Comparing Immediate Curative Therapy Versus Conservative Treatment in Men 75 Years and Older with High-Risk Non-Metastatic Prostate Cancer
Randomized Phase 3 Trial Measuring Survival and Quality of Life
Led by Sven Löffeler · Updated on 2026-09-10
980
Participants Needed
26
Research Sites
365 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatment options for older men aged 75 years or older with high-risk, non-metastatic prostate cancer. The study aims to compare immediate curative treatments like radiotherapy combined with hormone therapy or surgery to conservative approaches such as observation or hormone therapy. This trial addresses the uncertainty about whether immediate curative treatment offers survival benefits in older patients similar to those seen in younger men, while also considering quality of life and cost-effectiveness.
Participants randomized to the immediate curative therapy group will receive either radiotherapy plus hormone therapy or surgery based on patient preference, with radiotherapy plus hormone therapy being the standard. Those assigned to the conservative group will be observed or receive hormone therapy depending on disease status, with further treatment given based on disease progression. This phase 3 randomized trial compares these two approaches over an extended period.
Throughout the study, participants will be regularly evaluated for overall survival and disease burden up to 10 years after recruitment ends. Secondary assessments include monitoring urinary, bowel, and prostate cancer-related symptoms, quality of life, functional status, and the need for additional therapies. The study involves ongoing monitoring to understand long-term outcomes and side effects, supporting comprehensive assessment of treatment impact for this older population.
CONDITIONS
Brief Title
Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer
Research Team
S
Sven Loffeler, MD, PhD
E
Erik S Haug, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Male participants aged 75 years or older at the time of consent
Healthy based on medical evaluation and geriatric assessments (G8 score >14 or reversibly frail; miniCOG score >2)
Diagnosed with high-risk prostate cancer within the last 6 months, including Gleason grade 8-10 with palpable or MRI-visible tumor or locally advanced disease (T3 or T4)
Able to read, understand, and complete health-related quality of life questionnaires
Capable of providing signed informed consent
You will not qualify if you...
Diagnosis of dementia preventing informed consent
Prior radiation therapy to the pelvis
Hormone therapy for more than 3 months before randomization
Lymph node metastasis detected by imaging
Distant metastasis detected by imaging
Severe disability or comorbidities identified by G8 screening
Unable to read, understand, or complete quality of life questionnaires
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 10 years following recruitment
Participants receive either immediate curative therapy with radiotherapy plus hormone therapy or surgery, or conservative treatment with observation or hormone therapy based on random assignment.
Regular follow-up visits over 10 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
Sven Löffeler, Helena Bertilsson, Christoph Müller...